Subscribe to Journal
Get full journal access for 1 year
only $102.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Ayala F, Dewar R, Kieran M, Kalluri R . Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia 2009; 23: 2233–2241.
Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 2012; 119: 3917–3924.
Tavor S, Petit I, Porozov S, Avigdor A, Dar A, Leider-Trejo L et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res 2004; 64: 2817–2824.
Hanahan D, Weinberg RA . Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.
Chen WL, Wang JH, Zhao AH, Xu X, Wang YH, Chen TL et al. A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value. Blood 2014; 124: 1645–1654.
Akers LJ, Fang W, Levy AG, Franklin AR, Huang P, Zweidler-McKay PA . Targeting glycolysis in leukemia: a novel inhibitor 3-BrOP in combination with rapamycin. Leuk Res 2011; 35: 814–820.
Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 2005; 65: 613–621.
Samudio I, Fiegl M, McQueen T, Clise-Dwyer K, Andreeff M . The warburg effect in leukemia-stroma cocultures is mediated by mitochondrial uncoupling associated with uncoupling protein 2 activation. Cancer Res 2008; 68: 5198–5205.
Garrido SM, Appelbaum FR, Willman CL, Banker DE . Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol 2001; 29: 448–457.
Tamada M, Nagano O, Tateyama S, Ohmura M, Yae T, Ishimoto T et al. Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells. Cancer Res 2012; 72: 1438–1448.
Chen C, Liu Y, Liu R, Ikenoue T, Guan KL, Liu Y et al. TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. J Exp Med 2008; 205: 2397–2408.
Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA et al. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood 2012; 120: 2679–2689.
Spoo AC, Lubbert M, Wierda WG, Burger JA . CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 2007; 109: 786–791.
Dillenburg-Pilla P, Patel V, Mikelis CM, Zarate-Blades CR, Doci CL, Amornphimoltham P et al. SDF-1/CXCL12 induces directional cell migration and spontaneous metastasis via a CXCR4/Galphai/mTORC1 axis. FASEB J 2015; 29: 1056–1068.
Vander Heiden MG, Cantley LC, Thompson CB . Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029–1033.
MQ was supported by the IZKF Erlangen. RJ was supported by the ELAN program of the University of Erlangen. FAK was supported by the EC FP7-funded project RADIANT. DM was supported by the IZKF Erlangen and the Max-Eder program of the Deutsche Krebshilfe. We acknowledge the assistance of the Core Unit Cell Sorting and Immunomonitoring Erlangen.
MB performed research, analyzed data and helped writing the manuscript. MQ, MB, FK, DS and WH performed research and analyzed data. MA collected patient material and provided patient data. AM provided patient material and helped writing the manuscript. RJ performed research, helped designing the study and writing the manuscript. DM designed the study, analyzed data and wrote the manuscript.
The authors declare no conflict of interest.
Supplementary Information accompanies this paper on the Leukemia website
About this article
Cite this article
Braun, M., Qorraj, M., Büttner, M. et al. CXCL12 promotes glycolytic reprogramming in acute myeloid leukemia cells via the CXCR4/mTOR axis. Leukemia 30, 1788–1792 (2016). https://doi.org/10.1038/leu.2016.58
Journal of Cerebral Blood Flow & Metabolism (2019)
The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators
Biochemical Pharmacology (2019)
The Induction of a Permissive Environment to Promote T Cell Immune Evasion in Acute Myeloid Leukemia: The Metabolic Perspective
Frontiers in Oncology (2019)
Emerging Therapies for Acute Myelogenus Leukemia Patients Targeting Apoptosis and Mitochondrial Metabolism
Frontiers in Endocrinology (2019)